Safety, Tolerability, Pharmacokinetics, and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2014
At a glance
- Drugs EVP 0962 (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Adverse reactions; Pharmacodynamics
- Sponsors EnVivo Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 10 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Oct 2013 Planned end date changed from 1 Sep 2013 to 1 Jul 2014 as reported by ClinicalTrials.gov.